ArticleNeuropsychopharmacology reports2026
Associations Between Serum Adipokine, Antipsychotic Exposure, and Clinical Characteristics in Chronic Schizophrenia: A Cross-Sectional Study.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPrevious meta-analyses have reported lower serum adiponectin levels in patients with schizophrenia treated with second-generation antipsychotics. However, the relationships among serum adipokines, psychiatric symptoms, and antipsychotic use remain unclear. This study aimed to clarify associations between serum adipokines, psychiatric symptoms, and antipsychotic treatment in patients with chronic schizophrenia compared with healthy controls.
methodsThe study included 37 inpatients with schizophrenia and 39 age- and gender-matched healthy controls. Fasting blood samples were collected, and serum adipokine levels were measured using enzyme-linked immunosorbent assays. Psychiatric symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS), and antipsychotic doses were converted to chlorpromazine equivalents. Correlations were examined using regression and multivariate analyses, including adjustment for body mass index (BMI).
resultsNo significant case-control differences were observed in total or high-molecular weight adiponectin levels. Female patients had a significantly higher leptin/adiponectin ratio than female controls (p = 0.041). In the schizophrenia group, adiponectin levels were positively correlated with chlorpromazine equivalents (r = 0.684, p < 0.001). This association remained statistically significant after adjustment for BMI, gender and hospitalization period. Adiponectin levels were not significantly associated with psychiatric symptom severity.
conclusionIn this cross-sectional sample, serum adiponectin levels are associated with antipsychotic dosage but not with symptom severity. These findings suggest that adipokine regulation in patients with schizophrenia may be influenced by treatment-related and demographic factors. Longitudinal studies incorporating comprehensive metabolic assessments are needed to explore the clinical significance of these relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.